Pneumococcal Vaccines Market Snapshot
According to a survey conducted by ESOMAR-certified consulting firm Future Market Insights (FMI), the pneumococcal vaccines market value is expected to total US$ 10.1 Bn in 2021. Driven by the rising prevalence of pneumococcal diseases across the globe, sales of pneumococcal vaccines are poised to increase by a CAGR of 7.3% over the forecast period 2021-2031.
Favored by the increasing number of government initiatives and growing awareness regarding the benefits of early vaccination, the pneumococcal vaccines market is likely to register an impressive year-on-year growth at 9.60% in 2021.
Key Points Covered in Pneumococcal Vaccines Market Study
- Market estimates and forecast 2021-2031
- Key drivers and restraints impacting market growth
- Segment-wise, Country-wise, and Region-wise Analysis
- Competition Mapping and Benchmarking
- Brand share and Market Share Analysis
- Key Product Innovations and Regulatory Climate
- COVID-19 Impact on Pneumococcal Vaccines Market and How to Navigate
- Recommendation on Key Winning Strategies
Pneumococcal Vaccines Market Historic Outlook Compared to the Forecast Period 2021-2031
The pneumococcal vaccines market grew at 8.90% CAGR between 2016 and 2020. The growth of the market can be attributed to the increasing prevalence of pneumococcal diseases such as bacteremic pneumonia, bloodstream infection, meningitis, bacteremia, and middle ear infection.
According to a study by the National Foundation for Infectious Diseases (NFID), nearly 1.3 million people in the U.S. visit emergency departments due to pneumonia, which causes death of around 50,000 people. The fatality rate is even higher in patient aged above 65 years.
The rising number of smokers, diabetes patients, heavy drinkers, and individuals living with chronic health conditions, who are vulnerable to infections and ailments due to their weakened immune system will create demand for pneumococcal vaccines.
Some of the leading manufacturers are taking initiatives to curb the incidence of pneumococcal diseases in Gavi-supported countries. For instance, in January 2018, Pfizer, one of the global pharmaceutical leaders, announced reducing the price of its PCV-13 4 dose vial vaccine from US$ 3.05 to US$ 2.95 per dose in Gavi-supported countries.
These developments are expected to create growth opportunities, enabling the market to expand at a CAGR of 9.60% through 2031.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
What is the Impact of the Novel Coronavirus Outbreak on the Sales of Pneumococcal Vaccines?
The unprecedented outbreak of COVID-19 has substantially impacted the economies across the world. Various businesses and markets have been affected due to the regulatory lockdowns and imposed by the government, impeding the overall growth of industries.
However, the pandemic has positively impact the pneumococcal vaccines market, bolstering the sales over the past two years.
Some of the cases of novel coronavirus were placed in the same genre of diseases like pneumonia. Due to high similarities between coronavirus and pneumonia, medical professionals are increasingly using pneumococcal vaccines as a preventative measure against the high risk of lung infections caused by the disease.
According to a report published by World Health Organization (WHO) on 4th August 2021, approximately 199,466,211 cases has been confirmed across the globe with over 4,244,541 fatalities.
This rising cases of COVID-19 coupled with emerging new strains of coronavirus such asOC43, HKU1, and SARS-CoV among other is creating remunerative opportunities for the market.
How are Government Initiatives Driving Pneumococcal Vaccines Market?
Governments across various countries are adopting various initiatives to reduce the burden of pneumococcal diseases. For instance, in India, the Ministry of Health and Family Welfare (MoHFW) has undertaken initiative named, Social Action and Awareness to Neutralise Pneumonia Successfully (SAANS). The goal of SAANA is to spread the awareness regarding the routine pneumococcal immunization programs to curb the incidence of pneumonia.
Similarly, international organizations are contributing towards the goal. For instance, the WHO and United Nations Children’s Emergency Fund (UNICEF) have also introduced an initiative named, the Integrated Global Action Plan for the Prevention and Control of Pneumonia and Diarrhoea (GAPPD). The aim of GAPPD is to protect, prevent, and treat children from pneumonia and diarrhea.
Due to the efforts of these organization, several countries across the globe are progressively introducing pneumococcal conjugate vaccine (PCV) for infants and children aged from 6 weeks to 5 years for routine immunization and to prevent pneumococcal diseases and acute otitis media. As per a report by the World Health Organization (WHO), pneumococcal vaccine have been introduce in over 134 countries by the end of 2016 and covering about 42% of the world.
Thus, government initiatives are expected to help the pneumococcal vaccines market to expand over the coming year.
Why is Demand for Pneumococcal Vaccines Rising in the U.S.?
As per the FMI, the U.S. is anticipated to dominate the market in North America. The market for pneumococcal vaccines in the U.S. is bolstering due to high prevalence of pneumococcal disorders such as bacteremic pneumonia, bloodstream infection, and meningitis.
As per a report by the Centers of Disease Control and Prevention, more than 150,000 people in in the U.S. are hospitalized because of the pneumococcal pneumonia and around 3,500 people die due to pneumococcal meningitis and bacteremia. Thus, with the rise in prevalence of these diseases, the market in the U.S. is expected to expand at a rapid pace.
How is the Market for Pneumococcal Vaccines Flourishing in the U.K.?
In Europe, the U.K. is emerging as the most lucrative market on the back on presence of some of the leading pharmaceutical companies such as GlaxoSmithKline (GSK), AstraZeneca, Pfizer UK, and Shire.
Growing number of clinical trials and research and development activities for development of effective pneumococcal vaccines is estimated to provide enormous opportunities for the growth of the market. This will also fulfil the demand for vaccines for multiple serotypes in the country.
Owing to the presence of well-developed medical infrastructure and high consumer spending on the healthcare, the market in the U.K. is likely to project a steady growth over the coming years.
Why is the Demand for Pneumococcal Vaccines Spurring in India?
Issues concerning rising prevalence of pneumococcal diseases among children under the age of five have is increasing with urbanization in the country. As per a report published by Johns Hopkins Bloomberg School of Public Health named, Pneumonia & Diarrhea report 2020, India account for the largest number of deaths of children bellow 5 year out of 15 countries.
Thus to curb the burden of these diseases, government of the country is increasing undertaking initiatives to spread the awareness regarding the pneumococcal diseases.
For instance, Global Coalition against Child Pneumonia (GCCP) committee form by the government to promote interventions for protecting, preventing, and treating pneumonia is celebrating World Pneumonia Day in 12th November. This is to spread awareness regarding pneumonia and highlight the seriousness of disease as a public health problem across the country. Such initiatives are expected to propelling the demand for pneumococcal vaccines in India.
What are the Growth Prospects for Pneumococcal Vaccines Market in China?
A steady rise in investment across the medical healthcare has be witnessed in China, especially, due to the outbreak of coronavirus in the country. According to a report by WHO, around 121,067 cases of coronavirus has been reported in China with a 5,639 death over the last year.
Owing to the increasing use of pneumococcal vaccines by the medical institutes in the treatment of COVID-19, China is estimated to emerge as one of the most remunerative market in landscape.
Increasing number of medical institutes and hospitals in the country is also expected to bolster the sales of pneumococcal vaccines in the country.
Why is Demand for Pneumococcal Conjugate Vaccines High?
Pneumococcal conjugate vaccines are estimated to lead the product type, registering high growth in the global pneumococcal vaccines market.
Increasing adoption of pneumococcal conjugate vaccines for routine immunization of kids below 5 years to prevent them from fatal pneumococcal diseases and acute otitis media across the developing economies is projected to spur the sales.
In response to increasing number of research and development activities for developing new conjugate vaccines for expanding indications, the segment is likely to witness vigorous growth at through 2031.
Why do the Public Health Agencies Account for Maximum Share in Pneumococcal Vaccines Sales?
Among pharmacies, public health agencies, and community clinics, public health agencies are anticipated to account for the largest market share driven by the large amount of vaccine purchases by the organization such as WHO, GAVI, UNICEF, and other.
These organization purchase massive amount of pneumonia vaccines from the manufacturers to distribute them directly to the destination geographies for the social cause. Thus, on account of increasing number of initiatives undertaken by these organization, the segment is expected to emerge as the center point for the expansion of the market.
Leading players operating in the pneumococcal vaccines market are focusing on research and development for new product development to enhance their product portfolio and engaging into strategic collaboration, agreement, merger & acquisition with other market players to gain competitive edge over other players. For instance,
- Merck & Co., Inc., is focusing on developing new Merck’s V114, 15-valent pneumococcal conjugate vaccine. In September 2020, the company announced results for V114 from phase 2 & phase 3 studies and its respond on all 15 serotypes of pneumonia.
- In September 2020, Shinogi, a Japanese pharmaceutical company announced entering into a license agreement with a next-generation nasal vaccines manufacturer. HanaVax. The agreement with assist the company in R&D, manufacturing, commercialization, and distribution of Streptococcus pneumoniae developed by HanaVax.
Scope of Report
Historical Data Available for
USD Million for Value
Key Regions Covered
North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East & Africa
Key Countries Covered
US, Canada, Germany, U.K., France, Italy, Spain, Russia, China, Japan, South Korea, India, Thailand, Malaysia, Indonesia, Australia, New Zealand, GCC Countries, Turkey, Northern Africa, and South Africa
Key Segments Covered
Product Type, Distribution Channel, and Regions
Key Companies Profiled
Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing
Available upon Request
Key Questions Answered in the Report
What is the current value of pneumococcal vaccines market?
The pneumococcal vaccines market is expected to surpass a valuation of US$ 10124.9 in 2021.
At what rate did the pneumococcal vaccines market grow between 2016 and 2020?
The pneumococcal vaccines market witnessed impressive growth at 8.90% CAGR between 2016 and 2020.
What are the key trends driving pneumococcal vaccines sales?
Expansion of product indication and increasing Pharmacy-based Immunization Services (PBIS) will spur the sales.
Who are the leading players of pneumococcal vaccines?
GlaxoSmithKline Plc., Pfizer Inc., Merck & Co., Inc., and Sanofi SA. are the top players leading the pneumococcal vaccines market.
What is the demand outlook for North America pneumococcal vaccines market?
Demand for infant formula will continue to rise backed by rising prevalence of pneumococcal diseases in the country, sales across North America are set to surge at a robust CAGR of 8.25% through 2031.
What is the Europe market outlook for pneumococcal vaccines?
The market for pneumococcal vaccines in Europe will exhibit a steady growth at 7.39% CAGR during the forecast period 2021-2031.
Which are the top countries driving the pneumococcal vaccines market demand?
Top countries in terms of pneumococcal vaccines sales are the U.S., France, Germany, Canada, and the U.K.
What is the market share of leading players in pneumococcal vaccines market?
Leading players of global pneumococcal vaccines market is expected to contribute around 85-90% of total market share.
What is the current market share of Japan in the global pneumococcal vaccines market?
In 2021 key countries that are Japan and South Korea are estimated to account for 5% and less than 1% market share respectively in global pneumococcal vaccines market.
Pneumococcal Vaccines Market by Category
By Product Type:
- Pneumococcal Polysaccharide Vaccines
- Pneumococcal Conjugate Vaccines
By Distribution Channel:
- Community Clinics
- Public Health Agencies
- North America
- Latin America
- Asia Pacific Excluding Japan